重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 苏州泽璟生物制药股份有限公司 2025 年第三季度报告 证券代码：688266 证券简称：泽璟制药 苏州泽璟生物制药股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 217,789,855.47 | 51.85 | 593,440,129.02 | 54.49 | | 利润总额 | -20,904,645.94 | 不适用 | -9 ...

Core Viewpoint - Zai Jian Pharmaceutical's stock increased by 5.09% to 91.43 CNY per share, with a market capitalization of 24.202 billion CNY as of October 30 [1] Company Overview - Suzhou Zai Jian Biopharmaceutical Co., Ltd. was established on March 18, 2009, and went public on January 23, 2020 [1] - The company's main business involves the research, production, and sales of chemical new drugs and biological new drugs, with 99.97% of revenue coming from pharmaceuticals [1] Fund Holdings - One fund under Industrial Bank, the Industrial Medical Care A (011466), holds 143,000 shares of Zai Jian Pharmaceutical, unchanged from the previous period, representing 4% of the fund's net value [2] - The fund has a total size of 261 million CNY and has achieved a year-to-date return of 24.05% [2] - The fund manager, Chen Xu, has been in position for 4 years and 238 days, with the best and worst fund returns during his tenure being -19.16% and -21.01%, respectively [2]

Core Viewpoint - Zai Jian Pharmaceutical's stock increased by 5.09% to 91.43 CNY per share, with a trading volume of 279 million CNY and a market capitalization of 24.202 billion CNY as of October 30 [1] Company Overview - Suzhou Zai Jian Biopharmaceutical Co., Ltd. was established on March 18, 2009, and went public on January 23, 2020. The company focuses on the research, production, and sales of chemical and biological new drugs [1] - The main revenue composition of the company is 99.97% from pharmaceuticals, 0.02% from pharmaceutical intermediates and raw materials, and 0.00% from asset leasing [1] Fund Holdings - A fund under Bank of China Securities holds Zai Jian Pharmaceutical as one of its top ten holdings. The fund, Zhongyin Securities Health Industry Mixed Fund (002938), reduced its holdings by 4,000 shares in the third quarter, maintaining 128,000 shares, which accounts for 9.08% of the fund's net value, ranking it as the third-largest holding [2] - The fund has a total size of 159 million CNY and has achieved a year-to-date return of 39.48%, ranking 2223 out of 8152 in its category. Over the past year, it has returned 28.41%, ranking 3260 out of 8038, and since inception, it has returned 134.28% [2] Fund Manager Information - The fund manager of Zhongyin Securities Health Industry Mixed Fund (002938) is Li Mingwei, who has been in the position for 2 years and 252 days. The fund's total asset size is 159 million CNY, with the best and worst returns during his tenure being -5.4% [3]

Core Viewpoint - Suzhou Zelgen Biopharmaceutical Co., Ltd. will hold a Q3 2025 earnings presentation on November 5, 2025, to discuss its operational results and financial status for the third quarter of 2025, allowing investors to engage in Q&A sessions [2][3][6]. Group 1: Meeting Details - The earnings presentation will take place on November 5, 2025, from 16:00 to 17:00 [6][7]. - The meeting will be conducted in an interactive online format via the Shanghai Stock Exchange Roadshow Center [3][6]. - Investors can participate by logging into the Shanghai Stock Exchange Roadshow Center website [5][6]. Group 2: Investor Participation - Investors can submit questions from October 31, 2025, to November 4, 2025, before 16:00 through the Roadshow Center or via the company's email [2][8]. - The company will address commonly asked questions during the earnings presentation, within the limits of information disclosure [3][8]. Group 3: Participants - Key participants in the meeting will include the Chairman and General Manager Zelin Sheng, along with other executives and independent directors [4].

证券代码：688266 证券简称：泽璟制药 公告编号：2025-042 苏州泽璟生物制药股份有限公司 关于召开 2025 年度第三季度业绩说明会的公告 苏州泽璟生物制药股份有限公司（以下简称"公司"）将于 2025 年 10 月 31 日发布公司《2025 年第三季度报告》，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 5 日下午 16:00-17:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点、方式 （一）会议召开时间：2025 年 11 月 5 日（星期三）下午 16:00-17:00 ● 会议召开时间：2025 年 11 月 5 日（星期三）16:00-17:00 ● 会议召开地点：上证路演中心（http://roadshow.sseinfo.com） ● 会议召开方式：上证路演中心网络 ...

Group 1 - The core viewpoint of the news is that Zai Lab's stock has experienced fluctuations, with a notable decline in recent trading days despite a significant year-to-date increase [1][2] - As of October 28, Zai Lab's stock price was 99.80 CNY per share, with a market capitalization of 26.418 billion CNY [1] - The company has seen a year-to-date stock price increase of 60.17%, but has declined by 5.12% over the last five trading days, 7.15% over the last 20 days, and 17.59% over the last 60 days [1] Group 2 - For the first half of 2025, Zai Lab reported a revenue of 376 million CNY, representing a year-on-year growth of 56.07%, while the net profit attributable to shareholders was -72.8035 million CNY, a decrease of 9.42% year-on-year [2] - As of June 30, 2025, the number of shareholders increased by 16.75% to 8,795, while the average circulating shares per person decreased by 14.35% to 30,097 shares [2] - The top ten circulating shareholders include several funds, with notable changes in holdings, such as an increase in shares held by China Europe Medical Health Mixed A and a decrease in shares held by GF Healthcare Stock A [2]

Group 1 - The core viewpoint of the article highlights the performance of the Penghua Science and Technology Innovation 100 ETF, which reported a net value growth rate of 49.82% over the past year [1] - The fund's top ten holdings have seen changes, with new additions including Dongxin Co., Ltd., Yuanjie Technology, and Yuntian Lefe [1] - Huahong Technology remains the largest holding at 3.74% of the fund's portfolio, while Zexing Pharmaceutical, Naxin Micro, and Guodun Quantum have exited the top ten holdings [1] Group 2 - Detailed data on the fund's top holdings shows that Dongxin Co., Ltd. has entered the top ten with 1.872 million shares valued at 200 million yuan, and Yuanjie Technology has also entered with 362,500 shares valued at 156 million yuan [1] - Other notable changes include a reduction in holdings for Huahong Technology by 1.75%, with 2.4635 million shares valued at 282 million yuan, and a decrease in holdings for Baijie Shenzhou by 1.89% [1] - The fund's overall strategy reflects a shift in focus towards emerging technology companies, as indicated by the new additions and reductions in existing holdings [1]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [1] Core Insights - The report highlights significant advancements in innovative drugs, particularly in the context of recent clinical trial results presented at the 2025 ESMO conference, showcasing the potential for new treatment options in various cancer types [12][19] - The report emphasizes the emergence of domestic drugs that have achieved notable efficacy in treating conditions such as NSCLC and HER2-positive breast cancer, indicating a shift in the competitive landscape [13][17] Summary by Sections 1. New Drug Developments - **2L EGFR Mutant NSCLC**: The drug Lukanosumab (sac-TMT) is the first to demonstrate both overall survival (OS) and progression-free survival (PFS) benefits in patients with TKI-resistant NSCLC, with mPFS of 8.3 months compared to 4.3 months for chemotherapy [13][14] - **HER2 Positive Breast Cancer**: The drug Ruikang Trastuzumab shows longer mPFS of 30.6 months compared to 8.3 months for the chemotherapy combination, indicating a promising new option for patients [17][18] - **T-Bren for Breast Cancer**: Early data from the T-Bren trial shows a clinical overall response rate (cORR) of 82.2% in HER2-positive patients, with mPFS of 18.0 months [19][20] - **2L HER2 Positive Gastric Cancer**: Anniotuzumab combined with chemotherapy shows significant improvements in mPFS (7.1 months vs 2.7 months) and mOS (19.6 months vs 11.5 months), suggesting a potential shift in treatment paradigms [21][24] 2. Market Performance - The pharmaceutical and biotechnology sector saw a 0.58% increase in October, underperforming the CSI 300 index by 2.67 percentage points, ranking 25th among 31 sub-industries [25][30] - The medical research outsourcing sector experienced the highest growth, up 5.47%, while other bioproduct sectors faced declines [30][34]

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, indicating an "Overweight" rating for the industry, suggesting it is expected to outperform the overall market in the next six months [30]. Core Insights - The pharmaceutical sector saw a weekly increase of 0.6%, while the Shanghai Composite Index rose by 2.9% during the same period. The pharmaceutical index ranked 25th among 31 sub-industries [3][5]. - Notable collaborations include a strategic partnership between Innovent Biologics and Takeda Pharmaceutical, valued at up to $11.4 billion, which includes an upfront payment of $1.2 billion [4][13]. - Key clinical trial results presented at the 2025 ESMO conference highlighted significant advancements in cancer treatments, with several companies reporting promising outcomes in their respective studies [4][14][17]. Market Performance - The pharmaceutical sector's overall valuation stands at 30.4 times earnings, ranking 9th among 31 primary industries [7][5]. - Various sub-sectors showed mixed performance, with medical devices and medical consumables performing relatively well, while traditional Chinese medicine and chemical preparations faced declines [7][5]. Key Events - The report notes that 99 A-share pharmaceutical companies released their Q3 2025 earnings, with a total revenue of 94.15 billion yuan, reflecting a year-on-year growth of 1.3% [19][21]. - Significant clinical trial results from companies like Kintor Pharmaceutical and Zai Lab were highlighted, showcasing their innovative approaches to cancer treatment [14][17][18]. Company Recommendations - The report recommends focusing on innovative drug companies and those with improving performance in medical devices and CXO sectors, listing companies such as Hengrui Medicine, Changchun High-tech, and Mindray Medical as key investment targets [4][19].

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, indicating an "Overweight" rating for the industry, suggesting it is expected to outperform the overall market [32]. Core Insights - The report highlights that the Shenwan Pharmaceutical and Biological Index increased by 0.6% this week, while the Shanghai Composite Index rose by 2.9% and the Wind All A (excluding financials and petrochemicals) increased by 3.7% [4][6]. - The pharmaceutical sector's overall valuation stands at 30.4 times earnings, ranking 9th among 31 Shenwan primary industries [4][8]. - Significant collaborations and clinical trial results were reported, including a $11.4 billion global strategic partnership between Innovent Biologics and Takeda Pharmaceutical, which includes a $1.2 billion upfront payment [5][13]. - Key clinical trial results presented at the 2025 ESMO conference showed promising outcomes for several drugs, indicating advancements in treatment efficacy for various cancers [14][18][19]. Market Performance - The report details the performance of various sub-sectors within the pharmaceutical industry, with notable increases in medical devices (+0.2%), medical consumables (+1.7%), and medical research outsourcing (+5.5%), while traditional Chinese medicine and other biological products saw declines [4][8]. - The report also notes that 99 A-share pharmaceutical companies released their Q3 2025 earnings, with a total revenue of 94.15 billion yuan, reflecting a 1.3% year-on-year increase [20][22]. Key Events - The report mentions that Bairui Tianheng has passed the Hong Kong Stock Exchange hearing and is in the process of listing its H-shares [12]. - The report emphasizes the importance of the 2025 ESMO conference, where several companies presented significant clinical data, enhancing their market visibility and potential investment attractiveness [14][17][18]. Company Recommendations - The report recommends focusing on innovative drug sectors and companies with improving performance in medical devices and upstream sectors, including companies like Hengrui Medicine, Changchun High-tech, and Mindray Medical [5][20].